Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial
出版年份 2021 全文链接
标题
Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial
作者
关键词
-
出版物
BMJ Open Diabetes Research & Care
Volume 9, Issue 1, Pages e001990
出版商
BMJ
发表日期
2021-02-17
DOI
10.1136/bmjdrc-2020-001990
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Assessing the Risk for Gout With Sodium–Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes
- (2020) Michael Fralick et al. ANNALS OF INTERNAL MEDICINE
- Multicenter validation of association between decline in MRI‐PDFF and histologic response in nonalcoholic steatohepatitis
- (2020) Rohit Loomba et al. HEPATOLOGY
- A diabetologist’s perspective of non‐alcoholic steatohepatitis (NASH): Knowledge gaps and future directions
- (2020) Kenneth Cusi LIVER INTERNATIONAL
- SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
- (2020) Martin R. Cowie et al. Nature Reviews Cardiology
- Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease
- (2020) Jeffrey Budd et al. Current Diabetes Reports
- Role of ketogenic starvation sensors in mediating the renal protective effects of SGLT2 inhibitors in type 2 diabetes
- (2020) Milton Packer JOURNAL OF DIABETES AND ITS COMPLICATIONS
- The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients
- (2019) Aino Latva-Rasku et al. DIABETES CARE
- Glycemic Control, Preexisting Cardiovascular Disease, and Risk of Major Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: Systematic Review With Meta‐Analysis of Cardiovascular Outcome Trials and Intensive Glucose Control Trials
- (2019) Dario Giugliano et al. Journal of the American Heart Association
- Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis
- (2019) Jie Li et al. Lancet Gastroenterology & Hepatology
- Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial
- (2019) Sabine Kahl et al. DIABETES CARE
- Diabetes and Fatty Liver
- (2019) Norbert Stefan et al. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
- Pioglitazone for the primary and secondary prevention of cardiovascular and renal outcomes in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis
- (2019) Yue Zhou et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- When and how to use magnetic resonance elastography for patients with liver disease in clinical practice
- (2018) Sudhakar Kundapur Venkatesh et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
- (2018) Mohammad Shafi Kuchay et al. DIABETES CARE
- Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
- (2018) Jan W. Eriksson et al. DIABETOLOGIA
- Wisteria floribunda agglutinin-positive Mac-2-binding protein and type 4 collagen 7S: useful markers for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease
- (2018) Yuji Ogawa et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective, single-arm trial (LEAD trial)
- (2018) Yoshio Sumida et al. HEPATOLOGY RESEARCH
- Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies
- (2018) Norbert Stefan et al. Lancet Diabetes & Endocrinology
- Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes
- (2018) Kenneth Cusi et al. DIABETES OBESITY & METABOLISM
- Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis
- (2017) Michael S. Middleton et al. GASTROENTEROLOGY
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- (2017) Naga Chalasani et al. HEPATOLOGY
- Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels and liver fibrosis: A meta-analysis
- (2017) Kiyoaki Ito et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus
- (2016) Kenneth Cusi et al. ANNALS OF INTERNAL MEDICINE
- Glucagon and heart in type 2 diabetes: new perspectives
- (2016) Antonio Ceriello et al. Cardiovascular Diabetology
- Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes
- (2016) Romina Lomonaco et al. DIABETES CARE
- CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
- (2016) Ele Ferrannini et al. DIABETES CARE
- Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography
- (2016) Kento Imajo et al. GASTROENTEROLOGY
- Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes
- (2016) Zobair M. Younossi et al. HEPATOLOGY
- EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
- (2016) JOURNAL OF HEPATOLOGY
- Thiazolidinediones for nonalcoholic steatohepatitis
- (2016) Lingling He et al. MEDICINE
- Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis
- (2016) Jason H Y Wu et al. Lancet Diabetes & Endocrinology
- Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
- (2015) Sumio Watanabe et al. JOURNAL OF GASTROENTEROLOGY
- Elastography Assessment of Liver Fibrosis: Society of Radiologists in Ultrasound Consensus Conference Statement
- (2015) Richard G. Barr et al. RADIOLOGY
- Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome
- (2014) Hannele Yki-Järvinen Lancet Diabetes & Endocrinology
- Nonalcoholic Fatty Liver Disease: MR Imaging of Liver Proton Density Fat Fraction to Assess Hepatic Steatosis
- (2013) An Tang et al. RADIOLOGY
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
- (2010) Clifford J Bailey et al. LANCET
- Renal glucose transporters: novel targets for hyperglycemia management
- (2010) Amanda Mather et al. Nature Reviews Nephrology
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- (2010) Arun J. Sanyal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
- (2010) Giovanni Targher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: A multicenter validation study
- (2009) Ariel E. Feldstein et al. HEPATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started